Insulins are the standard therapy in patients with T1DM and are ultimately used in patients with T2DM who do not respond adequately to other treatment modalities. Although in some settings… read more →
The American Society of Clinical Oncology (ASCO) on Monday published a template for assessing new treatments based on the benefits and adverse events seen in clinical trials and on the… read more →
